 |
 |
The source of this article is uk.biz.yahoo.com: http://tinyurl.com/4tb92 Schwarz Pharma says US FDA accepts its NDA for Parkinson's drug Neupro MONHEIM, Germany (AFX) - Schwarz Pharma AG (Xetra: 722190.DE - news) said the US Food and Drug Administration has accepted its New Drug Application (NDA) for the Neupro patch, its rotigotine transdermal system to treat Parkinson's disease. The original application for the Neupro patch was filed in September last year. It was accepted by the European Medicines Evaluation Agency (EMEA), but the FDA refused to accept it due to electronic issues. Schwarz Pharma re-filed at the end of January. The patch has an annual peak sales potential of 350 mln eur, Schwarz Pharma said. The patch is applied once a day to the skin and administers the active ingredient rotigotine to the body for 24 hours. [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn